8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.